中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

206 records (took 0.037 seconds)

    ANTIGEN-NOROVIRUS P-DOMAIN MONOMERS AND DIMERS, ANTIGEN NOROVIRUS P-PARTICLE MOLECULES, AND METHODS FOR THEIR MAKING AND USE
    71.
    发明申请
    ANTIGEN-NOROVIRUS P-DOMAIN MONOMERS AND DIMERS, ANTIGEN NOROVIRUS P-PARTICLE MOLECULES, AND METHODS FOR THEIR MAKING AND USE 有权
    抗逆转录病毒双胞胎单体和二聚体，抗体抗原肽颗粒分子及其制备和使用方法

    公开(公告)号：US20130273090A1

    公开(公告)日：2013-10-17

    申请号：US13924906

    申请日：2013-06-24

    Applicant: Ming TAN ,  Xi Jiang

    Inventor： Ming TAN ,  Xi Jiang

    IPC: C07K7/06 ,  C07K5/10

    CPC classification number: C07K7/06 ,  A61K38/00 ,  A61K39/12 ,  A61K39/125 ,  A61K2039/5258 ,  A61K2039/542 ,  A61K2039/543 ,  A61K2039/55566 ,  A61K2039/58 ,  A61K2039/6075 ,  A61K2039/645 ,  A61K2039/70 ,  C07K5/10 ,  C12N2720/12334 ,  C12N2770/16034

    Abstract: A substituted Norovirus capsid protein monomer, having only the P-domain, includes a foreign antigen inserted into one or more of three surface loops present on each P-domain monomer by molecular cloning. The antigen-P-domain monomer can assemble spontaneously into an octahedral, antigen-Norovirus P-particle, composed of 24 copies of the monomer. Each substituted P-domain monomer can contain one to three copies of the foreign antigen, for a total of 24-72 antigen copies on each antigen-P-particle. The antigen-P-particle is useful in methods for diagnosing, immunizing and treating individuals infected with a foreign virus and as a carrier for development of vaccines against many infectious and non-infectious diseases. The substituted monomer can be readily produced in E. coli and yeast, are highly stable and tolerate a wide range of physio-chemical conditions. The P-particle-VP8 chimeras may also serve as a dual vaccine, for example, against both rotavirus and norovirus.

    Abstract translation: 仅具有P结构域的取代的诺如病毒衣壳蛋白单体包括通过分子克隆插入每个P-域单体上存在的三个表面环中的一个或多个的外源抗原。 抗原-P结构域单体可以自发组装成由24个单体组成的八面体抗原诺如病毒P颗粒。 每个取代的P-结构域单体可以含有一至三个拷贝的外源抗原，每个抗原-P-颗粒上共有24-72个抗原拷贝。 抗原-P颗粒可用于诊断，免疫和治疗感染外来病毒的个体的方法以及用于开发针对许多感染性和非感染性疾病的疫苗的载体。 取代的单体可以容易地在大肠杆菌和酵母中产生，高度稳定并且耐受广泛的生理化学条件。 P颗粒-PV8嵌合体也可以用作双重疫苗，例如针对轮状病毒和诺瓦病毒。

    THERMAL INACTIVATION OF ROTAVIRUS
    72.
    发明申请
    THERMAL INACTIVATION OF ROTAVIRUS 审中-公开
    罗非鱼的热灭活

    公开(公告)号：US20130149384A1

    公开(公告)日：2013-06-13

    申请号：US13718648

    申请日：2012-12-18

    Applicant: The Government of the United States of America, as represented by Secretary, Department of Health and Human Servi

    Inventor： Baoming Jiang ,  Roger I. Glass ,  Jean-Francois Saluzzo

    IPC: A61K39/15

    CPC classification number: A61K39/15 ,  A61K39/12 ,  A61K2039/5252 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/575 ,  C12N2720/12334

    Abstract: Methods of thermally inactivating a rotavirus are provided according to the present invention which include exposing the rotavirus to a temperature in the range of about 50° C.-80° C., inclusive, for an incubation time sufficient to render the rotavirus incapable of replication or infection. The thermally inactivated rotavirus is antigenic and retains a substantially intact rotavirus particle structure. Vaccine compositions and methods of vaccinating a subject against rotavirus are provided which include generation and use of thermally inactivated rotavirus.

    Abstract translation: 提供了根据本发明的热灭活轮状病毒的方法，其包括将轮状病毒暴露于约50℃-80℃范围内的温度，其温育时间足以使轮状病毒不能复制 或感染。 热灭活的轮状病毒是抗原性的并且保留基本上完整的轮状病毒颗粒结构。 提供疫苗组合物和接种患者抗轮状病毒的方法，其包括产生和使用热灭活的轮状病毒。

    LIVE ATTENUATED ROTAVIRUS VACCINE FOR ORAL ADMINISTRATION
    74.
    发明申请
    LIVE ATTENUATED ROTAVIRUS VACCINE FOR ORAL ADMINISTRATION 有权
    用于口腔管理的现有灭活罗非鱼疫苗

    公开(公告)号：US20120237547A1

    公开(公告)日：2012-09-20

    申请号：US13486039

    申请日：2012-06-01

    Applicant: Vincent VANDE VELDE

    Inventor： Vincent VANDE VELDE

    IPC: A61K39/15 ,  A61P1/00 ,  A61P31/14

    CPC classification number: A61K39/15 ,  A61K39/12 ,  A61K2039/5254 ,  A61K2039/542 ,  A61K2039/545 ,  C12N2720/12334

    Abstract: The invention provides liquid rotavirus formulations that are suitable for oral administration to human infants. In particular the invention provides pharmaceutical compositions and vaccines, comprising a rotavirus antigen, a sugar and a carboxylate wherein said formulation has a pH of between pH 5.0 and pH 8.0 and comprises no phosphate or less than 5 mM phosphate. The invention also provides methods of preparing said rotavirus formulations and use thereof in the prevention or treatment of rotavirus associated diseases in humans.

    Abstract translation: 本发明提供了适合于向人类婴儿口服给药的液体轮状病毒制剂。 特别地，本发明提供药物组合物和疫苗，其包含轮状病毒抗原，糖和羧酸盐，其中所述制剂具有pH5.0和pH8.0之间的pH，并且不包含磷酸盐或小于5mM磷酸盐。 本发明还提供了制备所述轮状病毒制剂及其在预防或治疗人类轮状病毒相关疾病中的用途的方法。

    Live attenuated rotavirus vaccine for oral administration
    75.
    发明授权
    Live attenuated rotavirus vaccine for oral administration 有权
    用于口服给药的活减毒轮状病毒疫苗

    公开(公告)号：US08192747B2

    公开(公告)日：2012-06-05

    申请号：US11816443

    申请日：2006-02-15

    Applicant: Vincent Vande Velde

    Inventor： Vincent Vande Velde

    IPC: C12N7/00

    CPC classification number: A61K39/15 ,  A61K39/12 ,  A61K2039/5254 ,  A61K2039/542 ,  A61K2039/545 ,  C12N2720/12334

    Abstract: This invention provides liquid rotavirus formulations that are suitable for oral administration to human infants. In particular, the invention provides pharmaceutical compositions and vaccines, comprising a rotavirus antigen, a sugar and a carboxylate, wherein said formulation has a pH of between pH 5.0 and pH 8.0 and comprises no phosphate or less than 5 mM phosphate. The invention also provides methods of preparing said rotavirus formulations and use thereof in the prevention or treatment or rotavirus associated diseases in humans.

    Abstract translation: 本发明提供了适合于口服给予人类婴儿的液体轮状病毒制剂。 特别地，本发明提供了包含轮状病毒抗原，糖和羧酸盐的药物组合物和疫苗，其中所述制剂具有pH5.0和pH8.0之间的pH，并且不包含磷酸盐或小于5mM磷酸盐。 本发明还提供了制备所述轮状病毒制剂及其在预防或治疗或轮状病毒相关疾病中的用途的方法。

    STABLE, DRIED ROTAVIRUS VACCINE, COMPOSITIONS AND PROCESS FOR PREPARATION THEREOF
    77.
    发明申请
    STABLE, DRIED ROTAVIRUS VACCINE, COMPOSITIONS AND PROCESS FOR PREPARATION THEREOF 有权
    稳定的罗非鱼疫苗，其制备方法及其制备方法

    公开(公告)号：US20110177119A1

    公开(公告)日：2011-07-21

    申请号：US13056557

    申请日：2009-11-06

    Applicant: Rajeev M. Dhere ,  Sambhaji S. Pisal ,  Jagdish K. Zade

    Inventor： Rajeev M. Dhere ,  Sambhaji S. Pisal ,  Jagdish K. Zade

    IPC: A61K39/21

    CPC classification number: A61K39/15 ,  A61K39/12 ,  A61K2039/5252 ,  C12N7/00 ,  C12N2720/12334 ,  C12N2720/12351

    Abstract: The present invention provides novel lyophilized rotavirus vaccine formulations and methods of their preparation. The formulations include vaccine stabilizers, resulting in a vaccine formulation with enhanced stability and minimal loss of potency. The rotavirus vaccine formulations comprise an advantageous ratio of a disaccharide (such as sucrose) to an amino acid (such as glycine). The lyophilization results in a virus formulation with 100% virus preservation and residual moisture from about 0.8% to 1.4%.

    Abstract translation: 本发明提供新的冻干轮状病毒疫苗制剂及其制备方法。 制剂包括疫苗稳定剂，产生具有增强的稳定性和最小的效力损失的疫苗制剂。 轮状病毒疫苗制剂包含二糖（例如蔗糖）与氨基酸（例如甘氨酸）的有利比例。 冷冻干燥导致具有100％病毒保存和残留水分的病毒制剂从约0.8％至1.4％。

Patent Agency Ranking